SOUTH SAN FRANCISCO, Calif., Oct. 12, 2016 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT ), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, today announced the expansion of its management team with the appointment of Tricia Suvari as chief legal officer.
“Tricia brings a wealth of experience managing the complex legal and business situations that arise in rapidly growing biopharmaceutical companies,” said Ted W. Love, M.D., president and chief executive officer of GBT. “Her knowledge and expertise managing business development opportunities, financings, and commercial compliance responsibilities will serve well in this role as we continue to grow as a company.”
Ms. Suvari has approximately 20 years of experience in the life sciences industry. She previously served in several senior roles at CV Therapeutics, ultimately as senior vice president, general counsel and chief compliance officer. At CV Therapeutics, she led the in-house legal team as the company transitioned from an R&D-stage company to a commercial-stage company with marketed products in the US and EU and multiple partnering arrangements. Prior to CV Therapeutics, she served as senior counsel at Genentech, where she completed many complex business development and licensing transactions and advised on legal compliance for several commercial products. She has also served as an independent consultant, supporting biopharmaceutical companies ranging from early-stage private companies to public companies. Most recently before joining GBT, Ms. Suvari served as a vice president and general counsel at the non-profit Peninsula Open Space Trust, where she led the land transactions team responsible for negotiating, structuring and funding complex conservation-oriented real estate transactions. Ms. Suvari earned her Bachelor of Sciences degree in Geology and Geophysics from Yale University and her J.D. degree from Harvard Law School.
About Global Blood Therapeutics Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is currently evaluating GBT440 in a Phase 1/2 study in both healthy subjects and adults with SCD and a Phase 2a study in adolescents with SCD. GBT is also investigating GBT440 for the treatment of hypoxemic pulmonary disorders in an ongoing Phase 2a study in patients with idiopathic pulmonary fibrosis. Additionally, GBT is also engaged in research and development activities with an oral kallikrein inhibitor for the prevention of hereditary angioedema attacks. To learn more, please visit: www.globalbloodtx.com .
Contact Information: Myesha Edwards (investors) Global Blood Therapeutics 650-351-4730 investor@globalbloodtx.com Julie Normart (media) BrewLife 415-946-1087 media@globalbloodtx.com
